arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Cue Biopharma, Inc.

CUE
$27.21 ▲ +0.20 (+0.72%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
38 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
13
Health
Poor
Bearish
auto_awesome

Analytical Summary

Cue Biopharma, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $130.8M
Dividend Yield
Revenue Growth 1250.6%
Op. Margin -94.1%
ROIC -19.6%
FCF / Share $-2.30
Trailing P/E
Price / Book 4.1x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

38-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$5.69M
↑ +1250.6%
Net Income Profit after all expenses
$-5.18M
↑ +57.8%
Operating Margin Operating profit as % of sales
-94.1%
↓ -1144.3% 2th
FCF / Share Free cash flow per share
$-2.30
↓ -1953.3%
Long-Term Debt Long-term obligations
$1.00M
↓ -50.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
3
Returns
8
Financial Health
9
Cash Quality
55

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 10 years · 38 quarters